AR113096A1 - Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos - Google Patents
Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacosInfo
- Publication number
- AR113096A1 AR113096A1 ARP180101987A ARP180101987A AR113096A1 AR 113096 A1 AR113096 A1 AR 113096A1 AR P180101987 A ARP180101987 A AR P180101987A AR P180101987 A ARP180101987 A AR P180101987A AR 113096 A1 AR113096 A1 AR 113096A1
- Authority
- AR
- Argentina
- Prior art keywords
- biodegradable
- range
- administration
- repeating units
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 14
- 229940079593 drug Drugs 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 229920000359 diblock copolymer Polymers 0.000 abstract 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001400 block copolymer Polymers 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 2
- 229920000728 polyester Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 229920000428 triblock copolymer Polymers 0.000 abstract 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960001929 meloxicam Drugs 0.000 abstract 1
- 229960005489 paracetamol Drugs 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
- C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee una composición biodegradable para la administración de fármacos que comprende: (i) una mezcla de por lo menos tres copolímeros de bloques diferentes, donde cada copolímero de bloques es: (a) un copolímero biodegradable de tribloques que tiene la fórmula: Aᵛ-Bʷ-Aˣ en donde A es un poliéster y B es polietilenglicol y v y x son entre 1 y 3.000 y w es entre 3 y 300 y v = x o v ¹ x; o (b) un copolímero biodegradable de dibloques que tiene la fórmula: Cʸ-Aᶻ en donde A es un poliéster y C es un polietilenglicol de extremos protegidos e y y z son el número de unidades repetitivas con y = 2 a 250 y z = 1 a 3.000; y en donde la mezcla comprende al menos un (a) y al menos un (b); y la proporción en peso entre (a) y (b) es entre 1:19 y 5:1; y para por lo menos uno de los copolímeros de acuerdo a (a) o (b) A es poli(ácido láctico-co-glicólico) (PLGA); y (ii) por lo menos un ingrediente farmacéuticamente activo. Reivindicación 8: Una composición biodegradable para la administración de fármacos de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque la composición además comprende: (a) un copolímero biodegradable de tribloques que tiene la fórmula: PLGAᵛ-PEGʷ-PLGAˣ en donde v y x son el número de unidades repetitivas que están en el rango entre 1 y 3.000 y w es el número de unidades repetitivas que están en rango entre 3 y 300 y v = x o v ¹ x; y/o (b) un copolímero biodegradable de dibloques que tiene la fórmula: mPEGʸ-PLGAᶻ en donde y y z son el número de unidades repetitivas con y en el rango entre 2 y 250 y z en el rango entre 1 y 3.000. Reivindicación 9: Una composición biodegradable para la administración de fármacos de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque la composición además comprende: y (a) un copolímero biodegradable de tribloques que tiene la fórmula: PCLAᵛ-PEGʷ-PCLAˣ en donde v y x son el número de unidades repetitivas que están en el rango entre 1 y 3.000 y w es el número de unidades repetitivas que están en rango entre 3 y 300 y v = x o v ¹ x; y/o (b) un copolímero biodegradable de dibloques que tiene la fórmula: mPEGʸ-PCLAᶻ en donde y y z son el número de unidades repetitivas con y en el rango entre 2 y 250 y z en el rango entre 1 y 3.000. Reivindicación 11: Una composición biodegradable para la administración de fármacos de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque dicha composición es un líquido inyectable y es adecuada para formas un depósito cuando se inyecta en el cuerpo, o son partículas sólidas pequeñas o implantes de varilla o formulaciones espaciales. Reivindicación 15: Una composición biodegradable para la administración de fármacos de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el ingrediente farmacéuticamente activo es meloxicam, acetaminofeno o combinaciones de los mismos. Reivindicación 31: Una composición biodegradable para la administración de fármacos de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque es adecuada para administración parenteral.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533370P | 2017-07-17 | 2017-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113096A1 true AR113096A1 (es) | 2020-01-29 |
Family
ID=63047314
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101988A AR113097A1 (es) | 2017-07-17 | 2018-07-17 | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
| ARP180101987A AR113096A1 (es) | 2017-07-17 | 2018-07-17 | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
| ARP180101986A AR113248A1 (es) | 2017-07-17 | 2018-07-17 | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101988A AR113097A1 (es) | 2017-07-17 | 2018-07-17 | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101986A AR113248A1 (es) | 2017-07-17 | 2018-07-17 | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11612563B2 (es) |
| EP (3) | EP3655037A1 (es) |
| JP (3) | JP7187738B2 (es) |
| KR (1) | KR20200032719A (es) |
| CN (1) | CN111107840A (es) |
| AR (3) | AR113097A1 (es) |
| AU (1) | AU2018304881B2 (es) |
| BR (1) | BR112020001031A2 (es) |
| CA (1) | CA3069787A1 (es) |
| EA (1) | EA202090161A1 (es) |
| IL (1) | IL271986B2 (es) |
| MX (1) | MX2020000618A (es) |
| TW (3) | TWI795421B (es) |
| WO (3) | WO2019016236A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113097A1 (es) * | 2017-07-17 | 2020-01-29 | Medincell | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
| GB201900258D0 (en) | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| US11680107B2 (en) * | 2019-03-22 | 2023-06-20 | Taipei Medical University | Hydrogel composition for drug delivery and uses thereof |
| US20220331240A1 (en) * | 2019-09-13 | 2022-10-20 | Medincell S.A. | Drug delivery formulations |
| GB202010340D0 (en) | 2020-07-06 | 2020-08-19 | Medincell | Pharmaceutical composition |
| EP4262749A1 (en) * | 2020-12-16 | 2023-10-25 | Medincell S.A. | Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19) |
| EP4014963A1 (en) * | 2020-12-16 | 2022-06-22 | Medincell | Pharmaceutical composition |
| GB202104224D0 (en) * | 2021-03-25 | 2021-05-12 | Medincell | Pharmaceutical composition |
| JP2024516264A (ja) * | 2021-04-30 | 2024-04-12 | メディンセル エスアー | 新規製剤 |
| AU2022323754A1 (en) | 2021-08-05 | 2024-02-08 | Medincell S.A. | Pharmaceutical composition |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113359A (en) | 1995-04-13 | 1999-06-20 | Univ Ben Gurion | Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| WO1999007343A1 (en) | 1997-08-08 | 1999-02-18 | University Of Utah Research Foundation | Injectable biodegradable block copolymer gels for use in drug delivery |
| US20020164374A1 (en) * | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| US7018645B1 (en) * | 2000-04-27 | 2006-03-28 | Macromed, Inc. | Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties |
| US20020192286A1 (en) * | 2001-03-27 | 2002-12-19 | Macromed, Incorporated | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
| IL151288A0 (en) | 2001-08-27 | 2003-04-10 | Yissum Res Dev Co | Multi-component reverse thermo-sensitive polymeric systems |
| US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| US20030228366A1 (en) | 2002-06-11 | 2003-12-11 | Chung Shih | Reconstitutable compositions of biodegradable block copolymers |
| US7649023B2 (en) | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| US20060034889A1 (en) | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| US20080247987A1 (en) | 2005-08-04 | 2008-10-09 | Angiotech International Ag | Block Copolymer Compositions and Uses Thereof |
| US8877223B2 (en) * | 2006-03-09 | 2014-11-04 | Coloplast A/S | Degradable hydrophilic block copolymers with improved biocompatibility for soft tissue regeneration |
| HUE035101T2 (hu) | 2007-09-28 | 2018-05-02 | Pfizer | Ráksejtek célzása nanorészecskék alkalmazásával |
| ES2324009B1 (es) | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| TWI388591B (zh) | 2008-03-28 | 2013-03-11 | Ind Tech Res Inst | 溫度敏感性材料 |
| US8956636B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
| US7993666B2 (en) | 2008-04-18 | 2011-08-09 | Warsaw Orthopedic, Inc. | Methods and compositions for treating pain comprising a statin |
| PT2774608T (pt) | 2008-06-16 | 2020-01-17 | Pfizer | Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas |
| US20100015049A1 (en) | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
| EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| US9295651B2 (en) | 2009-12-23 | 2016-03-29 | The Board Of Trustees Of The University Of Illinois | Nanoconjugates and nanoconjugate formulations |
| US20110319473A1 (en) | 2010-06-29 | 2011-12-29 | Surmodics, Inc. | Compositions and methods for enhancement of nucleic acid delivery |
| US9023897B2 (en) * | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| CN102058909A (zh) | 2011-01-18 | 2011-05-18 | 复旦大学 | 聚乙二醇－共聚酯嵌段共聚物防粘连材料及其制备方法与应用 |
| EP2691079B1 (en) | 2011-03-31 | 2020-06-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| US9795679B2 (en) * | 2011-03-31 | 2017-10-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| EP2674167A1 (en) | 2012-06-14 | 2013-12-18 | PLS-Design GmbH | Controlled activation of complement components for use as endogenous adjuvant |
| WO2014001904A1 (en) | 2012-06-27 | 2014-01-03 | Medincell | Biodegradable drug delivery for hydrophobic compositions |
| US8954932B2 (en) * | 2012-12-11 | 2015-02-10 | International Business Machines Corporation | Crash notification between debuggers |
| EP2983716A4 (en) | 2013-04-11 | 2017-01-25 | Commonwealth Scientific and Industrial Research Organisation | Composition for controlled delivery of bioactive agents |
| KR101512759B1 (ko) | 2013-08-30 | 2015-04-16 | 아주대학교산학협력단 | 이온성 작용기가 곁사슬 또는 말단에 도입된 온도감응성 폴리에틸렌글리콜/폴리에스터 블록 공중합체 및 이의 제조방법 |
| CN103601878B (zh) | 2013-11-25 | 2015-05-13 | 沈阳药科大学 | 高稳定性聚乙二醇-聚酯聚合物及其应用 |
| EP2918262B1 (en) | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
| CA2946155A1 (en) | 2014-04-18 | 2015-10-22 | Pfizer Inc. | Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation |
| US10780175B2 (en) | 2015-04-18 | 2020-09-22 | The Texas A&M University System | Polymer systems and their applications in diagnostics and drug delivery |
| EP3095440B1 (en) | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
| US20170209374A1 (en) | 2015-09-11 | 2017-07-27 | Pfizer Inc. | Methods of controlling the morphology of polymeric nanoparticles |
| AU2016355236C1 (en) * | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| US20170266187A1 (en) | 2016-03-15 | 2017-09-21 | Pfizer Inc. | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same |
| CN105878174B (zh) | 2016-04-26 | 2021-06-29 | 广州帝奇医药技术有限公司 | 一种固体分散体及其制备方法与应用 |
| CN105878191B (zh) | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 缓释微粒的制备方法、制得的缓释微粒及其应用 |
| CN105963258B (zh) | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| CN105963257B (zh) | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| WO2018039318A1 (en) | 2016-08-26 | 2018-03-01 | Akina, Inc. | Biodegradable polymer formulations for extended efficacy of botulinum toxin |
| AR113097A1 (es) * | 2017-07-17 | 2020-01-29 | Medincell | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos |
-
2018
- 2018-07-17 AR ARP180101988A patent/AR113097A1/es unknown
- 2018-07-17 JP JP2020503001A patent/JP7187738B2/ja active Active
- 2018-07-17 WO PCT/EP2018/069442 patent/WO2019016236A1/en unknown
- 2018-07-17 US US16/631,604 patent/US11612563B2/en active Active
- 2018-07-17 MX MX2020000618A patent/MX2020000618A/es unknown
- 2018-07-17 TW TW107124706A patent/TWI795421B/zh active
- 2018-07-17 CA CA3069787A patent/CA3069787A1/en active Pending
- 2018-07-17 JP JP2020502982A patent/JP7205019B6/ja active Active
- 2018-07-17 US US16/631,716 patent/US11801217B2/en active Active
- 2018-07-17 TW TW107124707A patent/TWI795422B/zh active
- 2018-07-17 BR BR112020001031-6A patent/BR112020001031A2/pt unknown
- 2018-07-17 EP EP18746857.4A patent/EP3655037A1/en active Pending
- 2018-07-17 EP EP18746859.0A patent/EP3655038A1/en active Pending
- 2018-07-17 EA EA202090161A patent/EA202090161A1/ru unknown
- 2018-07-17 WO PCT/EP2018/069440 patent/WO2019016234A1/en unknown
- 2018-07-17 AR ARP180101987A patent/AR113096A1/es unknown
- 2018-07-17 CN CN201880058018.3A patent/CN111107840A/zh active Pending
- 2018-07-17 AR ARP180101986A patent/AR113248A1/es unknown
- 2018-07-17 JP JP2020502983A patent/JP7210816B6/ja active Active
- 2018-07-17 AU AU2018304881A patent/AU2018304881B2/en active Active
- 2018-07-17 WO PCT/EP2018/069439 patent/WO2019016233A1/en unknown
- 2018-07-17 TW TW107124708A patent/TWI795423B/zh active
- 2018-07-17 KR KR1020207004586A patent/KR20200032719A/ko not_active Application Discontinuation
- 2018-07-17 EP EP18759254.8A patent/EP3655017A1/en active Pending
- 2018-07-17 US US16/631,586 patent/US11666527B2/en active Active
-
2020
- 2020-01-12 IL IL271986A patent/IL271986B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113096A1 (es) | Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos | |
| CU24203B1 (es) | Composiciones de suministro de fármacos biodegradables | |
| ES2390066T3 (es) | Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque | |
| EA201492172A1 (ru) | Биоразлагаемая композиция для доставки гидрофобных лекарственных средств | |
| EA202192099A2 (ru) | Системы доставки с замедленным высвобождением, содержащие бесследные линкеры | |
| PE20061204A1 (es) | Procedimiento para producir una forma farmaceutica protegida frente al uso fraudulento | |
| PE20060003A1 (es) | Formulacion farmaceutica polimerica para moldear por inyeccion | |
| PE20091184A1 (es) | Formas de dosificacion farmaceutica | |
| ES2721850T3 (es) | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas | |
| MY161930A (en) | Antipsychotic injectable depot composition | |
| CL2011000244A1 (es) | Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. | |
| BRPI0514297A (pt) | composições farmacêuticas para liberação controlada de compostos biologicamente ativos | |
| UY30431A1 (es) | Suspensiones acuosas de tmc278 | |
| PE20071139A1 (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
| AR052162A1 (es) | Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol | |
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| EA201890436A1 (ru) | Жидкая полимерная система доставки для длительного введения лекарственных средств | |
| RU2019107361A (ru) | Медленная локализованная доставка лекарственных средств, включая антибиотики | |
| AR116501A1 (es) | Sistema de suministro de polímero líquido para administración extendida de drogas | |
| RU2016149734A (ru) | Направленно доставляемые терапевтические наночастицы и способы их получения и использования | |
| MX2018008868A (es) | Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso. | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| AR123662A1 (es) | Composiciones y sistemas de polímeros y solventes biodegradables para un almacenamiento extendido y suministro de ingredientes farmacéuticos activos | |
| MX2020006188A (es) | Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada. | |
| MX2022003246A (es) | Composiciones de polimero liquido y sistemas para suministro prolongado de peptidos como ingredientes farmaceuticos activos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |